Pipeline
Pipeline
Sustainable Pipeline of Innovative Immunotherapies
We are developing next-generation immunotherapies that leverage our single-cell technologies and provide unique insights into immunomodulation.
Our sustainable pipeline of immunomodulatory antibodies targets multiple cell types and key immunosuppresive or inflammatory mechanisms for the treatment of cancer and autoimmune disease.
Our Pipeline
Solid Tumors
Stage
Mechanism of Action
Overview
Immuno-oncology
TNFR2 is a TNF receptor family member expressed on effector and regulatory T cells. , In tumors, TNFR2 is expressed more broadly on activated and exhausted T cells than other T cell costimulatory receptors. Therefore, targeting TNFR2 is anticipated to yield greater anti-tumor immunity by stimulating T-cell activation and proliferation in the tumor microenvironment than targeting other costimulatory receptors. Our First-in-Class agonistic anti-TNFR2 candidate antibody, HFB200301, binds potently and selectively to TNFR2, recognizes cyno TNFR2, and induces CD4 and CD8 T cell activation and proliferation cooperatively with TNFα without requiring crosslinking. In vivo, HFB200301 demonstrates potent antitumor activity alone and combined with anti-PD-1 and is well tolerated in mouse and NHPs.
We are developing an anti-TNFR2 monoclonal antibody, HFB200301, as a first-in-class therapeutic capable of co-stimulating T cell proliferation and displaying strong in-vivo anti-tumor immunity and good tolerability for the treatment of biomarker selected patients with advanced cancer.
Stage
Mechanism of Action
Overview
Immuno-oncology
HFB301001 is a novel fully human IgG1 class OX-40 agonistic antibody with an optimized pharmacological profile. In contrast to other anti-OX-40 antibodies, the agonistic activity of HFB301001 is further enhanced in the presence of the endogenous ligand OX-40L and does not result in reduced expression of OX-40 on T cells. HFB301001 demonstrated superior anti-tumor activity in a human OX-40 knock-in mouse model compared to a competitor antibody and is positioned as a best-in-class differentiated molecule for potentially better clinical activity. Identification of a biomarker predictive of response to HFB301001 is ongoing using HiFiBiO’s proprietary Drug Intelligent Science (DIS™) platform.
HFB301001 is under development as a potential novel treatment option for cancer coupled with patient stratification biomarkers in solid tumor indications.
Stage
Mechanism of Action
Overview
Immuno-oncology and Autoimmune Disease
HFB2006 is an inhibitory immune checkpoint expressed on B and T cells. Interaction of HFB2006 with its ligand provides an inhibitory signal to immune cells. Therefore, agonizing HFB2006 has the potential to dampen the immune system in auto-immune
diseases, while blocking the HFB2006 interaction with its ligand could restore anti-tumor immunity in oncology.
We have identified potent binders capable of blocking the interaction of ligand to its relevant receptor.
Mining the antibody repertoire of plasma cells and plasmablasts could enable the discovery of useful antibodies for therapeutic or research purposes…Read more
We are excited to share with the oncology research community at AACR updates for two of our preclinical development programs – HFB200603, a novel anti-BTLA blocking antibody on track for IND submission, and HFB101110, an anti-CCR8 depleting antibody that was recently licensed to FibroGen…Read more
Presenters: Juying Li, Qian Zhang, Bingqing Shen, Manan Shah, Mingjie Chen, Sharon Li, Ling Dong, Francisco Adrian, Liang Schweizer…Read more
Stage
Mechanism of Action
Overview
Immuno-oncology
Galactoside-binding lectin Galectin 9 (Gal-9) is a key pleiotropic immunosuppressive modulator present in the tumor microenvironment. High Gal-9 expression has been reported in different types of cancers including hematological malignancies and multiple solid tumors. Neutralization of Gal-9 has the potential to enhance anti-tumor immune responses in the tumor micro-environment. Our anti-Gal-9 blocking antibody, HFB200901, has demonstrated single agent anti-tumor activity in a mouse cancer model, offers improved survival in combination with anti-PD-1 therapy as compared to anti-PD-1 alone, and shows good tolerability in NHPs.
We are developing an anti-Gal-9 neutralizing antibody with single agent and combination anti-tumor activity and with potential as a first-in-class treatment for AML and solid tumors.
Stage
Mechanism of Action
Overview
Autoimmune diseases and hematological malignancies
HFB1002 is a GPCR expressed on B cells, as well as on follicular helper T cells. HFB1002 plays a key role in the migration of B cells to germinal centers and the production of autoantibodies. HFB1002 is implicated in several autoimmune diseases, such as Sjogren’s Syndrome, and in cancers such as B cell lymphomas and several solid cancer types, where it has been associated with metastasis and poor prognosis.
We have identified potent binders capable of blocking B cell migration and stimulating cell killing via ADCC, with potent in vivo activity.
Mining the antibody repertoire of plasma cells and plasmablasts could enable the discovery of useful antibodies for therapeutic or research purposes…Read more
Stage
Mechanism of Action
Overview
Immuno-oncology
HFB1011 is a GPCR with prevalent and highly specific expression on immunosuppressive tumor infiltrating regulatory T cells (Tregs) across different tumor types. Stimulation of HFB1011 by its ligand results in proliferation of Tregs in the tumor microenvironment and immune-suppression. Targeting and blockade by monoclonal antibodies of the mouse ortholog has shown anti-tumor activity in various syngeneic models. Targeting HFB1011 with an antibody able to mediate cell killing through antibody-dependent cellular cytotoxicity (ADCC) offers the potential to selectively deplete highly immunosuppressive Tregs in the tumor microenvironment and promote anti-tumor immunity.
We have identified potent binders capable of stimulating cell killing via ADCC and blocking the binding of the HFB1011 immunosuppresive ligand.
Mining the antibody repertoire of plasma cells and plasmablasts could enable the discovery of useful antibodies for therapeutic or research purposes…Read more
We are excited to share with the oncology research community at AACR updates for two of our preclinical development programs – HFB200603, a novel anti-BTLA blocking antibody on track for IND submission, and HFB101110, an anti-CCR8 depleting antibody that was recently licensed to FibroGen…Read more
Presenters: Roshan Kumar, Julie Prigent, Hombline Poullain, Ayrin Kök, Carine George, Sami Ellouze, Yun-Yueh Lu, Rebecca Silver, Clarisse Monchecourt, Ross Fulton, Qian Zhang, Nicola Beltraminelli, Bernhard Moser, Francisco Adrian, Liang Schweizer…Read more
Stage
Mechanism of Action
Overview
Immuno-oncology and Autoimmune Disease
HFB2006 is an inhibitory immune checkpoint expressed on B and T cells. Interaction of HFB2006 with its ligand provides an inhibitory signal to immune cells. Therefore, agonizing HFB2006 has the potential to dampen the immune system in auto-immune diseases, while blocking the HFB2006 interaction with its ligand could restore anti-tumor immunity in oncology.
We have identified potent binders capable of blocking the interaction of ligand to its relevant receptor.
Mining the antibody repertoire of plasma cells and plasmablasts could enable the discovery of useful antibodies for therapeutic or research purposes…Read more
Stage
Mechanism of Action
Overview
Early stage bispecific program focused on dual co-stimulation of dendritic and T cells
Stage
Mechanism of Action
Overview
Early stage program aiming at reversal of immunosuppression by macrophages
Stage
Mechanism of Action
Overview
Early stage program focused in restoring the functional activity of suppressed T cells
Stage
Mechanism of Action
Overview
Early stage program focused in restoring the functional activity of suppressed T and NK cells
Stage
Mechanism of Action
Overview
Early stage bispecific program focused on dual checkpoint blockade on Tcells
Featured Licensed Partners
Affiliated Programs
Discovery of Novel Targets Leading to a New Generation of Precision Immunotherapies
We take a multi-faceted approach to target the immune system, including key immunosuppressive cell types, suppressive and stimulatory pathways, and pleiotropic immune modulators, to shift the immune balance in cancer and autoimmune diseases.
Our target discovery approaches:
- Profiling of patient samples using our Drug Intelligent Science (DIS™) single-cell capabilities
- Collaborations with leading immunology and oncology key opinion leaders
- Target deconvolution using patients’ antibody repertoires
